口腔癌术后患者症状群与生活质量的相关性研究

目的:调查口腔癌患者治疗过程中的症状,探讨症状群种类及其与生活质量的相关性。方法:采用便利抽样法,选取某三级甲等医院口腔癌术后患者201例为研究对象,应用头颈癌安德森症状评估量表、华盛顿生活质量测评量表对其进行调查,分析二者相关性。结果:189例患者完成了问卷调查。口腔癌术后患者在疾病进展和治疗过程中存在多种症状,较严重的症状有吞咽咀嚼和发声讲话症状。探索性因子分析得出3个症状群,分别为口腔咽喉症状群、困倦-消化道症状群、疲劳-呼吸症状群。生存质量各维度得分及总分与3个症状群总分之间呈负相关(P<0.05)。结论:口腔癌患者在术后康复过程中存在影响生活质量的多个症状群,并且严重影响患者的生存质量。医护人员应把握这一特点,及时评估症状,积极管理症状群,提高患者的生存质量。     

Commentary on symptom experience of pulmonary arterial hypertension (PAH) patients

Pulmonary arterial hypertension (PAH) is a complex and rapidly progressing illness with few long-term treatment options to prolong life and improve quality of life. The complexity of the disease predisposes patients to a multitude of symptoms that have an effect on their biopsychosocial well-being. McDonough et al. have taken a qualitative approach to examine the dimensions of PAH symptomology. Using a telephone survey approach, 10 patients were questioned regarding their symptoms. Following coding and categorization of the responses, two main themes were found, "holding back" and redefining life.” The primary symptom associated with holding back was breathlessness. This symptom largely governed fears and behaviors associated with subthemes found within this main theme. Breathlessness also featured in the redefining life category; however, practical issues associated with medication and treatment were also assigned importance in this category by the study respondents. Symptoms of anxiety and depression were counteracted in many instances by a positive and sometimes stoic attitude toward the illness. This study presents important foundational information which will help direct further development of theoretical hypothesis related to PAH symptomology, as well as help focus clinical research toward venues that will enhance nursing care of this complex disease.     

Cancer-related fatigue

Approximately 1.3 million people in the United States will be diagnosed with cancer in 2003 and millions of other individuals are already living with the disease. Fatigue continues to be the most prevalent and disruptive symptom of cancer and its treatment regimens. Fatigue was the most frequent and distressing cancer-related symptom occurring in women with lung cancer, two times greater than the next symptom, pain, and remains one of the most common symptoms in newly diagnosed lung cancer patients at any stage of the disease. There are many causes of cancer-related fatigue including preexisting conditions, physical and psychological symptoms caused by cancer, and the consequences of cancer treatment. High levels of fatigue decrease quality of life, physical functional status, and symptom management. This article presents an evidenced-base review of cancer-related fatigue, strategies for the management of cancer-related fatigue, and recommendations for clinical practice.     

Pediatric palliative care: beyond the end of life

Palliative care is an emerging nursing specialty and is developing a dedicated spot in the field of pediatrics. As a specialty, palliative care focuses on quality of life and symptom management for patients who are living with chronic and life-threatening diseases. In pediatrics, advances in health care mean that many children are living longer with these conditions and could benefit from services that focus on quality of life and superior symptom management. Palliative care can be provided concurrently with curative therapies and is philosophically similar yet distinct from hospice services.     

Insomnia: An Underrecognized Nonmotor Symptom in Parkinson Disease

Insomnia is a highly prevalent nonmotor symptom among patients with Parkinson disease (PD) and significantly impacts their quality of life. It is typically an underdiagnosed and untreated symptom of PD. Accurate assessment, ruling out other potential etiologies, and a combination of nonpharmacologic and pharmacologic interventions are important strategies in the management of insomnia in patients with PD. The goal of treatment is to improve sleep duration, sleep quality, and overall quality of life. Nurse practitioners play an integral role in the recognition, assessment, and management of insomnia in PD.     

Tinnitus: patients do not have to 'just live with it'

Tinnitus is distressing and affects the quality of life for many patients. Because primary care physicians may be the entry point for patients seeking help for tinnitus, we urge them to acknowledge this symptom and its potential negative impact on the patient's health and quality of life. Physicians should actively listen to the patient and provide hope and encouragement, but also provide realistic expectations about the course of treatment. The patient must also understand that there may be no singular "cure" for tinnitus and that management may involve multidisciplinary assessment and treatment.     

Symptomkontrolle in der Finalphase

An appropriate medical treatment and care during the final phase can make a calm and peaceful dying possible. Aim of this review is to show the symptoms and treatment of patients with a far advanced disease in the last three days of life and to standardise terms used to describe the last period of life. There are definitions worked out for rehabilitation in palliative medicine, for the terminal phase and the final phase. We know that the final phase is a very dynamic process with sometimes a lot of symptoms and problems. Reasons for an "active" medical treatment in the last three days of life are, that new symptoms may occur or previous good controlled symptoms like pain, dyspnoea, vomiting, fear etc. can reappear, which could make a change or finishing of treatment necessary. The aim of palliative medicine is to improve the quality of life especially in the terminal phase. If we focus on the terminal phase most patients - even with cancer pain - can die peacefully and under good symptom control. The dynamic situation in the final phase and the ethical decisions force us to draw our attention to these patients and stay with them until they die. Humanity is besides a funded medical care essential in accompanying the patient in his last days of life. Until now there are not many clinical studies which can help us to find guidelines for the treatment in the last three days of live.     

Quality of life and symptom severity for individuals with chronic fatigue syndrome: findings from a randomized clinical trial.

OBJECTIVE: Chronic fatigue syndrome is a profoundly disabling condition characterized by severe, unrelenting fatigue and a number of other physical and cognitive symptoms. Currently, there is no cure or widely accepted treatment for chronic fatigue syndrome, and few rehabilitation programs exist to address quality of life issues in chronic fatigue syndrome. In the present randomized clinical trial, the effects of an integrative, consumer-driven rehabilitation program on quality of life and symptom severity for individuals with chronic fatigue syndrome were examined. METHOD: Forty-seven participants were randomly assigned to either an immediate program group (n = 23) or a delayed program control group (n = 24) and assessed with the Chronic Fatigue Syndrome Symptom Rating Scale and the Quality of Life Index before the program, after program participants completed the group phase, and after program participants completed the one-on-one phase. It was hypothesized that the program would lead to improvements in quality of life and an overall reduction in symptom severity. RESULTS: Linear growth models were estimated comparing program and control conditions over time using random-effects regression analyses. Significant condition by time interactions were observed for the main outcomes of symptom severity and overall quality of life. Effect sizes for these interactions involving symptom severity (Cohen's d = 0.71) and overall quality of life (Cohen's d = .66) were moderate. CONCLUSIONS: Findings indicate that consumer driven programs such as this one can have a positive impact on symptom severity and quality of life over time for individuals with chronic fatigue syndrome.     

Paediatric asthma: overcoming barriers to an improved quality of life

Paediatric asthma has a considerable impact on both society, in terms of healthcare resources, and patients and their families, in terms of impaired quality of life. The principal goals of asthma treatment are to achieve and maintain control of symptoms. Achieving these goals may involve long-term use of appropriate medication in the form of an inhaled corticosteroid (ICS) and a long-acting ss-agonist (LABA). However, many patients with paediatric asthma are not currently achieving symptom control. The main barriers to asthma control are underuse of effective therapies, inappropriate choice of drug delivery devices and a lack of patient or parent/guardian education regarding the disease and its treatment. By addressing and overcoming these barriers to asthma control, the quality of life of patients and their families may be significantly improved.     

Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting

Physical symptoms other than pain often contribute to suffering near the end of life. In addition to pain, the most common symptoms in the terminal stages of an illness such as cancer or acquired immunodeficiency syndrome are fatigue, anorexia, cachexia, nausea, vomiting, constipation, delirium and dyspnea. Management involves a diagnostic evaluation for the cause of each symptom when possible, treatment of the identified cause when reasonable, and concomitant treatment of the symptom using nonpharmacologic and adjunctive pharmacologic measures. Part I of this two-part article discusses fatigue, anorexia, cachexia, nausea and vomiting. Fatigue is the most common symptom at the end of life, but little is known about its pathophysiology and specific treatment. Education of the patient and family is the foundation of treatment with the possible use of adjunctive psychostimulants. Anorexia and cachexia caused by wasting syndromes are best managed with patient and family education, as well as a possible trial of appetite stimulants such as megestrol or dexamethasone. For appropriate pharmacologic treatment, it is helpful to identify the pathophysiologic origin of nausea in each patient.     

Top 10 Things Palliative Care Clinicians Wished Everyone Knew About Palliative Care

With a focus on improving quality of life for patients, palliative care is a rapidly growing medical subspecialty focusing on the care of patients with serious illness. Basic symptom management, discussions of prognostic understanding, and eliciting treatment goals are essential pieces in the practice of nearly all physicians. Nonetheless, many complex patients with a serious, life-threatening illness benefit from consultation with palliative care specialists, who are trained and experienced in complex symptom management and challenging communication interactions, including medical decision making and aligning goals of care. This article discusses the changing role of modern palliative care, addresses common misconceptions, and presents an argument for early integration of palliative care in the treatment of patients dealing with serious illness.     

Exploratory survey of patients’ needs and perceptions of psychosocial oncology

Cancer is a major disease that affects a significant proportion of the population worldwide. With a decrease in mortality due to advancements in oncology treatment, there is an expanding role for psychosocial oncology. A satellite clinic for medical treatment (only chemotherapy) of cancer is available at the Guelph General Hospital (GGH). Patients accessing the chemotherapy clinic at GGH have minimal access to psychosocial or supportive care and it is not known if the existing services are addressing the psychosocial symptoms of cancer patients. Participants were asked to complete an anonymous survey which included self-report measures of depression, symptom severity, quality of life, and social support while receiving treatment at this facility. There was a great deal of variability in the patients’ emotional symptoms at this satellite clinic, though many patients reported emotional difficulties. Greater social work presence may lead to better identification of patients who would benefit from psychosocial oncology services.     

Clinical and urodynamic evaluations of urinary disorders in multiple sclerosis

Urinary dysfunction is a major clinical problem and a significant cause of disability in multiple sclerosis (MS) patients. Indeed, the bothersome symptom of urinary dysfunction may adversely affect social relationships and activities in MS patients. Since many causes of urinary dysfunction are described, a thorough evaluation including history, clinical examination and evaluation of quality of life is necessary. Generally, diagnosis of urinary disorders is complex with intricated pathophysiologic factors. In these cases, urodynamic investigations are necessary to better understand symptoms pathophysiology and choose the best treatment.     

Diagnosis, treatment and management of pruritus

Pruritus is a ubiquitous symptom with a wide range of presentations, often causing considerable distress for many individuals and resulting in reduced quality of life. In recent years there has been renewed interest and increased research activity in this previously neglected field. Although there is still much to be learnt about the mechanisms of pruritus, appropriate nursing interventions can be pivotal to the success of treatment. This article focuses primarily on the diagnosis, treatment and management of pruritus resulting from common dermatological causes. Key aspects of effective management of pruritus include individualized management and holistic assessment. The words 'pruritus' and 'itch' are used synonymously in this article.     

Multiple sclerosis-related fatigue

Fatigue is a significant factor in the lives of many MS patients and the most commonly reported symptom in many studies. Fatigue is an important symptom to consider because it affects patients' social lives, occupations, and activities of daily living. Efforts to predict fatigue have been mixed, but it appears to be related to overall quality of life and mood. From a pathophysiologic perspective, fatigue in MS is multifactorial and complex,involving dysregulation of the immune system, changes in the nervous system related to the disease process, neuroendocrine and neurotransmitter changes, and other factors such as physical deconditioning, sleep disturbance, pain, and medication side effects. Various attempts to assess fatigue have been made, and many measures are now available for use in clinical practice and research. In clinical practice, these measures help guide treatment considerations. Recent research has provided valuable strategies to ameliorate fatigue in MS, and although many patients continue to experience fatigue despite interventions, many receive substantial relief.Nonpharmacologic approaches-considered the first step in treatment-include exercise programs, cooling, dietary considerations, and energy conservation strategies. For patients who continue to experience significant fatigue, several medications (although not specifically approved for use in the reduction of MS-related fatigue) have proved effective in this regard.The first-line agents include amantadine for mild fatigue and modafinil for more severe cases. Second-line agents include pemoline and antidepressant medications. Other pharmacologic agents have also shown some promise.     

A systems science approach to fatigue management in research and health care

The purpose of this article was to highlight innovative analytic approaches in symptom science. Complex systems modeling is discussed using fatigue as an example. Fatigue is a common symptom among individuals of any age. It can be acute or chronic, and it can vary across the day and on weekends compared with weekdays. Fatigue can overlap with other symptoms, has many dimensions, and impacts daily function as well as society at large. With the complexities surrounding symptom science, innovative models are needed to advance our understanding of factors within the person, contextual and situational factors, and workplace or health care system factors that impact the symptom experience. Advances in methodologies, such as complex systems modeling, allow for more innovative methods to study the complexities of the symptom experience, design better ways to intervene and manage symptoms, and ultimately improve outcomes related to symptom management, quality of life, and health care utilization.     

Caring for Older Patients on Peritoneal Dialysis at End of Life

End of life is the last phase of life, not merely the last few days. For many older patients on peritoneal dialysis (PD), the end-of-life phase commences with the start of dialysis. The principal aim of management of this phase should be optimizing the quality of life of the patient. Evidence suggests that patients on dialysis mostly want involvement in decisions at this stage, but most do not have the opportunity to do so. Management should therefore include discussions with the patient and their family to determine lifestyle goals, treatment wishes, and ceilings of care (including resuscitation and dialysis withdrawal). Care should also include symptom identification and management, psychosocial support, and adaptation of dialysis to the ability and needs of the patient. By doing this, quality of life at end of life is achievable.     

芳香化酶抑制剂治疗期间乳腺癌患者症状群对生活质量的影响

目的 探讨乳腺癌患者在接受芳香化酶抑制剂（aromatase inhibitor,AI）治疗期间所出现的症状群及生活质量,并分析症状群与生活质量的相关性。方法 采取横断面调查,选取2020年4月—2021年1月就诊于北京市某肿瘤专科医院乳腺中心门诊患者260例。采用一般情况调查表、安德森症状量表、简明健康调查量表进行调查。 结果 回收有效问卷254份。通过主成分分析,提炼出3组症状群：病感症状群、治疗相关-心理症状群、消化系统症状群。患者简明健康调查量表生理健康、心理健康得分分别为（38.51±12.03）分、（43.06±14.29）分。多元线性回归分析显示,病感症状群越重、治疗相关-心理症状群越重、体重指数越高、文化程度越低,患者的生理健康越差;随着口服AI时间的延长,生理健康会有所改善。治疗相关-心理症状群越重,则患者的心理健康越差。 结论 乳腺癌患者在接受AI治疗期间存在多组症状群,症状群与生活质量呈负相关。医护人员应关注接受AI治疗患者,有必要制订针对性的干预措施,以缓解症状群并改善患者的生活质量。     

SKYPE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: Effectiveness and Comparison with Face-to-Face Treatment

Gut-focused hypnotherapy is an effective treatment for irritable bowel syndrome but is not widely available. This study assessed whether providing hypnotherapy by Skype might partially overcome this problem. Using a 50-point or more reduction in the IBS Symptom Severity Score as the primary outcome measure, 65% of subjects responded to Skype hypnotherapy with all other outcomes significantly improving. The primary outcome figure for face-to-face hypnotherapy was 76%. When other outcome scores for Skype and face-to-face treatment were compared, the mean changes were these: symptom severity (?94.1 vs. ?129.2), noncolonic score (?52.3 vs. ?64.8), quality of life (+56.4 vs. +66.2), anxiety (?3.3 vs. ?3.0), depression (?1.7 vs. ?2.5), and a 30% or more pain reduction (44% vs. 62%). Skype hypnotherapy is effective but slightly less so than face-to-face treatment. However, many patients would have been unable to access treatment without the Skype option.